ID: h-9b0771a001
Hypothesis
Perturbation-first validation should precede therapeutic claims for Proteogenomic Network Hubs as Druggable Targets in Early PD Neurodegeneration
The debate supports treating this as a validation program before ranking it as a therapy.
🩺 neurodegeneration🎯 Composite 61%💱 $0.56▼8.4%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 1 support✗ 1 oppose
🧪 Overview
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.
🧬 Mechanism
No curated mechanism pathway recorded for this hypothesis.
⚖️ Evidence
⚖️ Evidence Matrix1 supports1 contradicts
Supports
The proposed priority experiment is concrete: multi-omics network centrality, druggability scoring, interactome validation, and SNCA iPSC-neuron perturbation assays
Contradicts
Therapeutic tractability is not established by the current source evidence.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for this gene.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.7%
Volatility
Low
0.0016
Events (7d)
3
Price History
▼8.4%💾 Resource Usage
LLM Tokens
172,526
$0.6062
API Calls
85
Total Cost
$0.6062
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.